Biohaven Pharmaceuticals

delay FDA delay
Biotech

FDA delays decision on Biohaven troriluzole filing, plans adcomm

Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA has delayed a decision on its rare disease drug troriluzole.
Nick Paul Taylor May 15, 2025 6:02am
brain money funding

Biohaven lands funding Oberland funding deal worth up to $600M

Apr 28, 2025 4:43pm
long shot miss basketball hoop fail shoot

Biohaven's biopolar med fails pivotal test

Mar 3, 2025 5:14pm
plan B fail reroute road path trail miss

Biohaven fails phase 3 SMA test but plans talks with FDA

Nov 25, 2024 9:56am
Graphic image of an arrow nailing the bullseye of a target

Biohaven bounces back with phase 3 ultra-rare disease win

Sep 23, 2024 9:22am
long distance runners race ultramarathon marathon

Immunovant promotes next-gen FcRn drug in race to rival Vyvgart

May 30, 2024 7:02am